Prot #UBX1325-02: Phase 2a, Prospective, Multicenter, Randomized, Double Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema,

Project: Research project

Project Details

Effective start/end date6/29/216/29/24


  • Rho, Inc ((OE) Prot #UBX1325-02 // (OE) Prot #UBX1325-02)
  • Unity Biotechnology, Inc ((OE) Prot #UBX1325-02 // (OE) Prot #UBX1325-02)